611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Obesity All on Its Own Can Raise Your Health Risks1 in 4 U.S. Adults Sits More Than 8 Hours a DayAnother Dry Eye Harm: Slowed ReadingHealth Tip: Help Fight Fatty Liver DiseaseWorried About the Salmonella Scare With Turkey This Holiday? Don't BeAHA: Have Diabetes? Make Sure to Manage Cholesterol, TooHealth Tip: When to Get the Shingles VaccineNearly 1 in 12 U.S. Kids Has a Food AllergyNew Treatment Could Be Breakthrough Against Peanut AllergyHere's More Evidence Obesity Can Shorten Your LifeHealth Tip: Treat LaryngitisCan EpiPens Still Work After Freezing?Pets Can Double as Asthma AntidoteDining Out With Allergies Is Tough, But These Steps Can HelpAHA: Achilles Tendon May Be Window Into Heart Disease SeverityClimate Change Could Change the Ragweed Sneezin' SeasonHealth Tip: Think You Have a Broken Toe?Why Are So Few COPD Patients Getting Vital Rehab Treatment?Monkeys Can Carry Zika Virus, Scientists DiscoverYou May Be Prediabetic and Don't Know It, CDC WarnsGoodbye 'Gluten-Free'? Celiac Disease Vaccine May Make It PossibleTwo Factors at Birth Can Boost a Child's Obesity RiskCDC Probe Continues as Cases of Polio-Like Illness Rise in KidsEven Young Football Players Not Immune to Damage From Head InjuriesCould a Natural Protein Help Fight Obesity?Tough-to-Treat UTIs More Likely to RecurConcussion Tied to Suicide RiskAHA: 3 Things to Know About CholesterolMajor Injuries Take a Toll on Mental HealthSome Activity Fine for Kids Recovering From Concussions, Docs SayArm Yourself Against the Coming Flu SeasonNew Cholesterol Guidelines Focus on Personalized ApproachChange Within the Eye May Be Early Warning for Macular DegenerationDead End for Treatment of Polio-Like Disorder Striking KidsNew Ebola Test Produces Results in Remote AreasHealth Tip: Symptoms of Kidney StonesHealth Tip: Warning Signs of Carpal Tunnel SyndromeTennis Elbow 'Treatments' Bring Little Relief: StudyHealth Tip: Keep Toxins from Your HomeSmoking, Diabetes May Be Especially Risky for Women's HeartsBlood Test May One Day Help Track Concussion RecoveryYour Showerhead May Be Bathing You in GermsWorst Bedsores Still Plague U.S. Hospital Patients: StudyHealth Tip: Use Petroleum Jelly to Protect Your SkinHome Health-Care Tests: Proceed With CautionSmartphones, Summer Birth Could Raise Kids' Odds for NearsightednessHigh Blood Pressure in Young Adults Tied to Earlier StrokesOver 2 Million Americans Have Hepatitis C; Opioids Help Drive SpreadHealth Tip: Tracking High TriglyceridesHealth Tip: Understanding Autoimmune Disorders
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

3-Drug Therapy Might Be Cystic Fibrosis 'Breakthrough'

HealthDay News
by By Amy Norton
HealthDay Reporter
Updated: Oct 18th 2018

new article illustration

THURSDAY, Oct. 18, 2018 (HealthDay News) -- In what researchers are calling a "breakthrough," two preliminary trials have found that either of two triple-drug regimens could potentially benefit 90 percent of people with cystic fibrosis.

The trials were short-term, finding that the drug combinations improved adult patients' lung function over four weeks. But experts said they were optimistic the results will hold up in the larger, longer-term trials already underway.

What's most exciting, they said, is that the triple-drug approach could open up new options to nearly all cystic fibrosis patients.

"This is not a cure for cystic fibrosis," stressed Dr. Steven Rowe, who led one of the trials. "But it could be game-changing."

Cystic fibrosis (CF) is a genetic disorder that causes persistent lung infections. Over time, extensive lung damage leads to respiratory failure. At one time, children with CF usually died before they reached school age. But with improved treatments, the typical life expectancy is now about 40 years, according to the Cystic Fibrosis Foundation.

Cystic fibrosis is caused by various mutations in a gene called CFTR. In the past several years, drugs that target those underlying genetics have become available. Known as CFTR modulators, they were heralded as a major advance in treating the disorder.

However, they work well only for a small number of people with certain CFTR mutations, explained Rowe, director of the Cystic Fibrosis Research Center at the University of Alabama at Birmingham.

The most common mutation that causes cystic fibrosis is called F508del -- and it has proven tougher to tackle, Rowe said.

About half of people with CF carry two copies of the mutation (one inherited from each parent). For them, a combination of two existing CFTR modulators can ease breathing problems -- but the overall effects are only "modest," Rowe said.

Then there's the 30 percent of CF patients who carry only one copy of F508del, plus another defect known as a "minimal-function" mutation. For them, the existing CFTR modulators do not work at all.

Both new trials focused on those two groups of patients. The results are published in the Oct. 18 New England Journal of Medicine, to coincide with the researchers' presentation at a North American Cystic Fibrosis meeting, in Denver.

Rowe's team tested a combination of two available CFTR modulators -- tezakaftor and ivakaftor -- plus an experimental one, known as VX-659. The other trial used the same existing drugs, along with a similar new drug, dubbed VX-445.

Rowe's team randomly assigned 54 adults with cystic fibrosis to either take the triple-drug regimen or be in a comparison group. In the comparison group, patients with one F508del mutation took placebo pills, while patients with two copies of the mutation took tezakaftor and ivakaftor alone.

After four weeks, the trial found, the triple-drug therapy had improved lung function in patients with both types of mutations. Their performance on a test called FEV1 rose by as much as 13 percentage points, on average -- what Rowe described as a "pronounced improvement."

The other trial had nearly identical results.

This is the first time, Rowe said, that CFTR modulator therapy has "pushed the needle" for patients with one F508del mutation.

An editorial published with the studies said they "represent a major breakthrough."

Now the questions are whether the improved lung function can be sustained, and whether the drugs prevent symptom exacerbations and other complications, wrote Dr. Fernando Holguin, of the University of Colorado, Aurora.

The Cystic Fibrosis Foundation helped fund the work through a grant to Vertex Pharmaceuticals, Inc., which is developing both experimental drugs.

"The ability of these potential drugs to treat individuals with a single F508del mutation means that more people than ever before could benefit," said Dr. Michael Boyle, senior vice president for therapeutics at the foundation. "This is very exciting news for our community."

Rowe agreed there are still important questions about the triple-drug regimens. One is, how well do they work for younger patients?

Patients as young as 12 are included in the larger ongoing trials, Rowe said.

So far, the treatments appear safe. Most side effects in the four-week trials were "mild to moderate," the researchers said, and included cough, headache and increased sputum.

If the experimental drugs are ultimately approved, there will be the real-world issue of price.

Vertex currently markets the combination of tezakaftor and ivakaftor as Symdeko -- at a reported list price of $292,000 a year.

In the United States, more than 30,000 people have cystic fibrosis, according to the foundation.

More information

For an overview of cystic fibrosis, visit the Cystic Fibrosis Foundation.